Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability